EXTON, PA — ProRx Pharma is moving to disrupt one of the fastest-growing corners of the medical wellness industry with the launch of an oral NAD+ formulation designed to deliver the benefits of cellular therapy without needles, clinic visits, or daily injections.
NAD+, short for nicotinamide adenine dinucleotide, is a molecule critical to cellular energy production, DNA repair, and metabolic health. Levels decline with age, a drop that has been linked to fatigue, slower recovery, and cognitive changes. Until now, most medical-grade NAD+ therapy has relied on injections or infusions, formats that are costly, time-consuming, and difficult to scale.
ProRx’s new liquid oral delivery system is aimed at breaking that bottleneck.
“Our oral NAD+ formulation offers a convenient alternative to injectable options, giving healthcare providers a way to deliver high-quality cellular support that aligns with today’s performance-focused wellness programs,” said Kurt Lunkwitz, chief operating officer of ProRx Pharma.
The company says its proprietary liquid system delivers stable, consistent doses of NAD+ in a daily 1 mL ampule, allowing clinics to integrate the therapy into telemedicine, maintenance care, and high-performance protocols without the sterility risks or in-office time required for injectable products.
From a business standpoint, the move targets a market that has been growing rapidly as longevity, cognitive health, and metabolic optimization become mainstream priorities among consumers. By shifting NAD+ from an in-clinic procedure to a take-at-home therapy, ProRx is betting it can help providers reach more patients at lower cost while preserving clinical-grade quality.
The formulation is produced in ProRx’s FDA-registered, state-licensed 503B outsourcing facility and compounded under U.S. Pharmacopeia <795> and current Good Manufacturing Practice standards. Each batch undergoes third-party testing for potency, purity, stability, and bioburden, a level of quality control designed to appeal to physicians and regulated medical practices.
ProRx says the oral NAD+ therapy is intended to support energy, cognition, muscle recovery, cardiovascular health, and long-term cellular resilience, positioning it as a core offering for clinics focused on preventive and performance medicine.
By turning a needle-based therapy into a shelf-stable liquid, ProRx is attempting to redraw the economics of NAD+ treatment. If the formulation performs as advertised, it could push cellular health therapies out of specialty clinics and into a much broader, more scalable healthcare market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.